Compare · MVIS vs TMO
MVIS vs TMO
Side-by-side comparison of MicroVision Inc. (MVIS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MVIS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 6944.3x MVIS ($37.1M).
- MVIS has been more active in the news (9 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 2 for MVIS).
- Company
- MicroVision Inc.
- Thermo Fisher Scientific Inc
- Price
- $1.16-7.60%
- $690.13-0.92%
- Market cap
- $37.1M
- $257.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 9
- 7
- Recent ratings
- 2
- 25
MicroVision Inc.
MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was incorporated in 1993 and is headquartered in Redmond, Washington.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MVIS
- MicroVision to Announce Third Quarter 2026 Financial Results on October 28, 2026
- MicroVision IRIS Long-Range Lidar Selected by Overland AI for Its Next-Gen IBEX Autonomous Ground Vehicle
- SEC Form 8-K filed by MicroVision Inc.
- MicroVision Reaffirms 2026 Revenue Outlook, Outlines Commercial Growth, and Path to Profitability
- MicroVision and Robinson Unmanned Advance Lidar Integration for Real-Time Aerial Mapping
- Director Biddiscombe Simon converted options into 16,067 shares, increasing direct ownership by 59% to 43,218 units (SEC Form 4)
- MicroVision Updates Start Time for Video Session & Business Update on October 7, 2026
- MicroVision CEO, CFO, and CCO to Host Video Session & Business Update on October 7, 2026
- MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture
- MicroVision IRIS Long-Range Lidar Selected for Advanced Autonomous Ground Vehicle Defense Applications
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)